Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials - Top-Institutions - MDSpire

Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

  • By

  • Jerry Bagel

  • Ranga Gogineni

  • Asif Shaikh

  • Mark G. Lebwohl

  • March 16, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Immunology
    • Endocrinology

  • #2

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Endocrinology

  • #3

    Harvard Medical School / Massachusetts General Hospital
    Harvard Medical School / Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Dermatology
    • Immunology
    • Endocrinology

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Dermatology
    • Immunology
    • Endocrinology

  • #5

    University of California, San Francisco (UCSF) School of Medicine
    University of California, San Francisco (UCSF) School of Medicine

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Endocrinology

Original Source(s)

Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

  • by Jerry Bagel, Ranga Gogineni, Asif Shaikh, Mark G. Lebwohl

  • March 16, 2026

Related Content

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial

Survey on Real-World Interventions and Strategies for Treat-to-Target Approaches in Psoriasis Management in Canada